Current Vaccines
AIDSVAX Vaccine
Canarypox HIV Vaccine
The AIDSVAX vaccines were developed by the biopharmaceutical company VAXGen, an offshoot from Genentech. The vaccine was designed to spur the production of antibodies that would remove the gp120 protein off a HIV viral cell, which would inable the virus from binding and invading susceptible cells. The vaccine is similar to the vaccines for small pox, polio, measles and othere diseases in that it induces antibodies. AIDSVAX is made of gp120, the very proteins that coat the HIV virus, in order to boost immune response to the virus. Trials were conducted when the vaccine was released. The results showed that AIDSVAX didn't
The canarypox HIV vaccine was developed by Sanofi Pasteur. The company created this pox virus to induce cellular responses and prime for antibody responses which is helped by recombinant proteins, thus providing the best immunological response to HIV. A trial known as RV 144 was conducted with this vaccine in Thailand in 2003 and resuts were tested for in 2006. The report showed that the rate of HIV infection among volunteers who received the vaccine was 31% lower than the rate of those who received placebo. (#47)
significantly reduce the HIV infection but certain ethnicities responded differently to the vaccine; Blacks and Asians produced higher levels of antibodies while Whites and Hiapanics produced a consistently low level of protective antibodies. (#46)